Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01065623 (Clinical Trial/ BAY79-4620)

Study Title
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors (NCT01065623)

Trial Description
Clinical study to determine safety, tolerability, to measure how the drug is metabolized by the body and to determine the maximum tolerated dose of BAY79-4620 given every 2 weeks to patients with advanced solid tumors. This trial is sponsored by Bayer. [1]

Study Data

  • Condition: Neoplasms
  • Interventions:
    • Drugs used in this trial
      • BAY79-4620
  • Phase: I
  • Enrollment: 2
  • Start: April 2010
  • Completion: August 2010
  • Last verified: September 2014

Study Schematic

 Screen Shot 2016-07-06 at 4.31.25 PM

 

Click here to Return to Drug map


Last Editorial review: July 7, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar